UBS Group AG Increases Stock Holdings in Cerus Corporation $CERS

Posted by Francis Steltz on May 28th, 2026

UBS Group AG boosted its position in shares of Cerus Corporation (NASDAQ:CERS – Free Report) by 227.1% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 1,142,502 shares of the biotechnology company’s stock after acquiring an additional 793,244 shares during the quarter. UBS Group AG owned about 0.59% of Cerus worth $2,354,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Round Rock Advisors LLC acquired a new stake in Cerus during the 4th quarter worth about $545,000. CWM LLC lifted its position in Cerus by 6.8% during the 4th quarter. CWM LLC now owns 129,084 shares of the biotechnology company’s stock worth $266,000 after acquiring an additional 8,178 shares during the period. Bingham Private Wealth LLC acquired a new stake in Cerus during the 4th quarter worth about $40,000. SG Americas Securities LLC lifted its position in Cerus by 52.9% during the 4th quarter. SG Americas Securities LLC now owns 61,268 shares of the biotechnology company’s stock worth $126,000 after acquiring an additional 21,206 shares during the period. Finally, Assenagon Asset Management S.A. lifted its position in Cerus by 5.8% during the 4th quarter. Assenagon Asset Management S.A. now owns 1,676,279 shares of the biotechnology company’s stock worth $3,453,000 after acquiring an additional 92,577 shares during the period. Institutional investors and hedge funds own 78.37% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the company. BTIG Research raised Cerus from a “neutral” rating to a “buy” rating and set a $4.00 price target for the company in a research report on Friday, May 1st. Zacks Research raised Cerus from a “strong sell” rating to a “hold” rating in a research report on Thursday, April 30th. Weiss Ratings reissued a “sell (d-)” rating on shares of Cerus in a report on Wednesday, March 25th. Finally, Wall Street Zen upgraded Cerus from a “hold” rating to a “buy” rating in a research note on Saturday, May 2nd. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $4.00.

Get Our Latest Analysis on Cerus

Insider Buying and Selling

In related news, CEO William Mariner Greenman sold 447,757 shares of the company’s stock in a transaction dated Thursday, March 12th. The stock was sold at an average price of $1.66, for a total value of $743,276.62. Following the completion of the transaction, the chief executive officer owned 4,998,493 shares of the company’s stock, valued at approximately $8,297,498.38. This represents a 8.22% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Richard J. Benjamin sold 101,740 shares of the company’s stock in a transaction dated Thursday, March 12th. The stock was sold at an average price of $1.66, for a total value of $168,888.40. Following the completion of the transaction, the insider directly owned 777,361 shares of the company’s stock, valued at $1,290,419.26. The trade was a 11.57% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 1,210,949 shares of company stock worth $2,156,291 in the last ninety days. 5.60% of the stock is owned by corporate insiders.

Cerus Trading Up 3.3%

Shares of NASDAQ:CERS opened at $2.82 on Thursday. Cerus Corporation has a 12-month low of $1.15 and a 12-month high of $3.15. The company has a market capitalization of $565.04 million, a PE ratio of -56.40 and a beta of 1.62. The business has a 50 day moving average of $2.14 and a two-hundred day moving average of $2.11. The company has a current ratio of 1.63, a quick ratio of 1.06 and a debt-to-equity ratio of 0.47.

Cerus (NASDAQ:CERS – Get Free Report) last announced its quarterly earnings results on Thursday, April 30th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.02. The company had revenue of $59.89 million during the quarter, compared to the consensus estimate of $55.68 million. Cerus had a negative return on equity of 15.18% and a negative net margin of 4.41%. As a group, analysts forecast that Cerus Corporation will post -0.02 EPS for the current year.

Cerus Company Profile

(Free Report)

Cerus Corporation is a biomedical products company dedicated to enhancing the safety of blood transfusions worldwide. Its flagship offering, the INTERCEPT Blood System, employs pathogen reduction technology designed to inactivate a broad spectrum of viruses, bacteria, and parasites in donated platelets and plasma. This approach aims to mitigate the risk of transfusion-transmitted infections and improve blood component safety for patients.

The INTERCEPT platform integrates seamlessly into existing blood center workflows, providing a one-step treatment process for collected blood products.